Host Immune Responses to Surface S-Layer Proteins (SLPs) of

Overview

Journal Microorganisms

Specialty Microbiology

Date 2023 Feb 25

PMID 36838345

Authors

Harish Chandra

Rhett A Kovall

Jagjit S Yadav

Xingmin Sun

Affiliations

Soon will be listed here.

Abstract

, a nosocomial pathogen, is an emerging gut pathobiont causing antibiotic-associated diarrhea. infection involves gut colonization and disruption of the gut epithelial barrier, leading to the induction of inflammatory/immune responses. The expression of two major exotoxins, TcdA and TcdB is the major cause of pathogenicity. Attachment of bacterial abundant cell wall proteins or surface S-layer proteins (SLPs) such as SlpA with host epithelial cells is critical for virulence. In addition to being toxins, these surface components have been shown to be highly immunogenic. Recent studies indicate that SLPs play important roles in the adhesion of the bacteria to the intestinal epithelial cells, disruption of tight junctions, and modulation of the immune response of the host cells. These proteins might serve as new targets for vaccines and new therapeutic agents. This review summarizes our current understanding of the immunological role of SLPs in inducing host immunity and their use in the development of vaccines and novel therapeutics to combat infection.

Citing Articles

Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against Infection.

Wang S, Heuler J, Bullock J, Qin J, Chakraborty S, Nathaniel A Vaccines (Basel). 2025; 13(1).

PMID: 39852800 PMC: 11768939. DOI: 10.3390/vaccines13010021.

PPAR-γ agonist mitigates intestinal barrier dysfunction and inflammation induced by Clostridioides difficile SlpA in vitro.

Noori M, Azimirad M, Ghorbaninejad M, Meyfour A, Zali M, Yadegar A Sci Rep. 2024; 14(1):32087.

PMID: 39738433 PMC: 11686163. DOI: 10.1038/s41598-024-83815-4.

, a New "Superbug".

Markovska R, Dimitrov G, Gergova R, Boyanova L Microorganisms. 2023; 11(4).

PMID: 37110267 PMC: 10140992. DOI: 10.3390/microorganisms11040845.

References

Negm O, Hamed M, Dilnot E, Shone C, Marszalowska I, Lynch M . Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray Analysis. Clin Vaccine Immunol. 2015; 22(9):1033-9. PMC: 4550668. DOI: 10.1128/CVI.00190-15. View

Kirby J, Ahern H, Roberts A, Kumar V, Freeman Z, Acharya K . Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem. 2009; 284(50):34666-73. PMC: 2787329. DOI: 10.1074/jbc.M109.051177. View

Collins L, Lynch M, Marszalowska I, Kristek M, Rochfort K, OConnell M . Surface layer proteins isolated from Clostridium difficile induce clearance responses in macrophages. Microbes Infect. 2014; 16(5):391-400. DOI: 10.1016/j.micinf.2014.02.001. View

Li Y, Cai H, Wang Z, Xu J, Fang J . Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther. 2015; 43(4):445-57. DOI: 10.1111/apt.13492. View

Mori N, Takahashi T . Characteristics and Immunological Roles of Surface Layer Proteins in Clostridium difficile. Ann Lab Med. 2018; 38(3):189-195. PMC: 5820062. DOI: 10.3343/alm.2018.38.3.189. View

Noori M, Azimirad M, Eslami G, Azizmohammad Looha M, Yadegar A, Ghalavand Z . Surface layer protein A from hypervirulent Clostridioides difficile ribotypes induce significant changes in the gene expression of tight junctions and inflammatory response in human intestinal epithelial cells. BMC Microbiol. 2022; 22(1):259. PMC: 9608920. DOI: 10.1186/s12866-022-02665-0. View

Mayer B . SH3 domains: complexity in moderation. J Cell Sci. 2001; 114(Pt 7):1253-63. DOI: 10.1242/jcs.114.7.1253. View

Wullt M, Noren T, Ljungh A, Akerlund T . IgG antibody response to toxins A and B in patients with Clostridium difficile infection. Clin Vaccine Immunol. 2012; 19(9):1552-4. PMC: 3428380. DOI: 10.1128/CVI.00210-12. View

Fagan R, Janoir C, Collignon A, Mastrantonio P, Poxton I, Fairweather N . A proposed nomenclature for cell wall proteins of Clostridium difficile. J Med Microbiol. 2011; 60(Pt 8):1225-1228. DOI: 10.1099/jmm.0.028472-0. View

10.

Lawson P, Citron D, Tyrrell K, Finegold S . Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O'Toole 1935) Prévot 1938. Anaerobe. 2016; 40:95-9. DOI: 10.1016/j.anaerobe.2016.06.008. View

11.

Ryan A, Lynch M, Smith S, Amu S, Nel H, McCoy C . A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins. PLoS Pathog. 2011; 7(6):e1002076. PMC: 3128122. DOI: 10.1371/journal.ppat.1002076. View

12.

Chandra H, Sharma K, Tuovinen O, Sun X, Shukla P . Pathobionts: mechanisms of survival, expansion, and interaction with host with a focus on . Gut Microbes. 2021; 13(1):1979882. PMC: 8565823. DOI: 10.1080/19490976.2021.1979882. View

13.

Tam Dang T, de la Riva L, Fagan R, Storck E, Heal W, Janoir C . Chemical probes of surface layer biogenesis in Clostridium difficile. ACS Chem Biol. 2010; 5(3):279-85. DOI: 10.1021/cb9002859. View

14.

Leav B, Blair B, Leney M, Knauber M, Reilly C, Lowy I . Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine. 2009; 28(4):965-9. DOI: 10.1016/j.vaccine.2009.10.144. View

15.

Shirvan A, Aitken R . Isolation of recombinant antibodies directed against surface proteins of Clostridium difficile. Braz J Microbiol. 2016; 47(2):394-402. PMC: 4874623. DOI: 10.1016/j.bjm.2016.01.017. View

16.

Lanzoni-Mangutchi P, Banerji O, Wilson J, Barwinska-Sendra A, Kirk J, Vaz F . Structure and assembly of the S-layer in C. difficile. Nat Commun. 2022; 13(1):970. PMC: 8881574. DOI: 10.1038/s41467-022-28196-w. View

17.

Fagan R, Fairweather N . Clostridium difficile has two parallel and essential Sec secretion systems. J Biol Chem. 2011; 286(31):27483-93. PMC: 3149341. DOI: 10.1074/jbc.M111.263889. View

18.

Luo Y, Frey E, Pfuetzner R, Creagh A, Knoechel D, Haynes C . Crystal structure of enteropathogenic Escherichia coli intimin-receptor complex. Nature. 2000; 405(6790):1073-7. DOI: 10.1038/35016618. View

19.

Vardakas K, Polyzos K, Patouni K, Rafailidis P, Samonis G, Falagas M . Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012; 40(1):1-8. DOI: 10.1016/j.ijantimicag.2012.01.004. View

20.

Fagan R, Albesa-Jove D, Qazi O, Svergun D, Brown K, Fairweather N . Structural insights into the molecular organization of the S-layer from Clostridium difficile. Mol Microbiol. 2009; 71(5):1308-22. DOI: 10.1111/j.1365-2958.2009.06603.x. View